TICKERNERD
Menu
CTNMCTNMHealthcare · Biotechnology

CTNM Stock Forecast: Contineum Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 14 Aug 2026
$14
−7.25% on the day

The 8 Wall Street analysts covering Contineum Therapeutics, Inc. hold a median 12-month price target of $23 — +62.1% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 60 of 100 as at 15 Aug 2026 — in the upper half.

Market cap
$533.8M
Ticker Nerd rank
60 / 100
Median analyst target
$23
Analysts covering
8
Total return, dividends reinvested
1W
−5.7%
1M
−2.6%
YTD
+24.1%
1Y
+95.5%
From 52W high
−13.4%
From 52W low
+95.5%
$7
$16
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

CTNM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Contineum Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Aug 2026
60 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
95
Volatility
69
Growth
65
Revisions
62
Quality
53
Size
53
Value
49
Accruals
33
Issuance
25

Momentum (95): The shares have been drifting up relative to others.

Issuance (25): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CTNM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CTNM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$15$20$25$30Oct 25Jan 26Apr 26Jul 26CTNMHigh $28Median $23Low $16

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says8 analysts
7 Buy1 Hold0 Sell
Low $16Median $23High $28

The green dot is the last close — the median target sits +62.1% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
31 July 2026RBC CapitalMaintainsOutperform$22 → $23
14 May 2026Morgan StanleyMaintainsEqual-Weight$14 → $16
14 May 2026Morgan StanleyMaintainsEqual-Weight—
6 Mar 2026BairdMaintainsOutperform—
8 Jan 2026Morgan StanleyDowngradeEqual-Weight—
24 Nov 2025BairdMaintainsOutperform—
21 Nov 2025RBC CapitalMaintainsOutperform—
25 Sept 2025Leerink PartnersInitiatesOutperform—
18 Aug 2025Morgan StanleyMaintainsOverweight—
19 May 2025Morgan StanleyMaintainsOverweight—
15 May 2025RBC CapitalReiteratesOutperform—
13 Mar 2025Jones TradingInitiatesBuy—
7 Mar 2025BairdMaintainsOutperform—
7 Mar 2025Morgan StanleyAssumesOverweight$25
9 Jan 2025RBC CapitalReiteratesOutperform—
7 Nov 2024RBC CapitalMaintainsOutperform—
22 Oct 2024BairdInitiatesOutperform—
14 Aug 2024RBC CapitalMaintainsOutperform—
30 Apr 2024Morgan StanleyInitiatesOverweight—
30 Apr 2024RBC CapitalInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CTNM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CTNM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
7
Analysts cutting
0
Fundamentals

Contineum Therapeutics, Inc. (CTNM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
26.0×

Cheaper than 31% of US stocks

Price / sales
—
Price / book
2.2×

Cheaper than 44% of US stocks

EV / EBITDA
−4.6×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−28.0%

Higher than 28% of US stocks

Return on assets
−19.2%

Higher than 20% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

CTNM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CTNMContineum Therapeutics, Inc.$533.8M
60
ARTVArtiva Biotherapeutics, Inc.$556.3M
38
SPRYARS Pharmaceuticals, Inc.$558.5M
13
PRMEPrime Medicine, Inc.$560.5M
35
ALTAltimmune, Inc.$571.4M
23
ZURAZura Bio Ltd.$528.5M
32
OVIDOvid Therapeutics, Inc.$528.2M
67

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Contineum Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CTNM news & analysis

Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones

Business Wire · 30 July 2026neutral

Contineum Therapeutics reported its second-quarter 2026 financial results and affirmed its key clinical development milestones, including the PROPEL-IPF global Phase 2 trial evaluating PIPE-791 for fibrotic diseases.

Why it matters — A CTNM watcher would care because the company reaffirmed its key clinical milestones for PIPE-791, a pipeline candidate in a Phase 2 trial for a disease with significant unmet need.

FAQ

Frequently asked questions about CTNM stock

What is the CTNM stock price forecast for 2026-2027?

The 8 Wall Street analysts covering Contineum Therapeutics, Inc. have a median 12-month price target of $23, with estimates ranging from $16 to $28. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is CTNM stock a buy right now?

Of the 8 analysts covering Contineum Therapeutics, Inc., 7 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Contineum Therapeutics, Inc. 60 out of 100 across roughly 4,600 US stocks as at 15 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank CTNM?

As at 15 Aug 2026, Contineum Therapeutics, Inc. ranks 60 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (95 of 100).

Will CTNM stock go up?

No one can know that. What the data says: the median 12-month target from 8 analysts implies +62.1% from the last close, and Ticker Nerd's factor model ranks Contineum Therapeutics, Inc. 60 out of 100 as at 15 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the CTNM stock forecast for 2030?

No analyst covering Contineum Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CTNM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $16 to $28 over the next 12 months.

How has CTNM stock performed over the past year?

Contineum Therapeutics, Inc. returned +95.5% over the 12 months to 14 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Contineum Therapeutics, Inc. do?

Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions.

What is the latest news on CTNM?

The most recent item we track (Business Wire, 30 July 2026): "Contineum Therapeutics Reports Second-Quarter 2026 Financial Results; Affirms Key Clinical Development Milestones". Contineum Therapeutics reported its second-quarter 2026 financial results and affirmed its key clinical development milestones, including the PROPEL-IPF global Phase 2 trial evaluating PIPE-791 for fibrotic diseases.

Company

About Contineum Therapeutics, Inc.

Continua Therapeutics Inc. is a biotechnology company focused on the development and commercialization of innovative therapeutic solutions. Its primary function lies in advancing novel drug candidates aimed at addressing unmet medical needs within the healthcare sector. The company emphasizes research and development, with a focus on diseases that currently lack effective treatment options, potentially impacting various medical fields such as oncology, neurology, and autoimmune disorders. Continua Therapeutics Inc. is significant in the market due to its commitment to pioneering next-generation pharmaceuticals that could redefine standard treatment protocols. Through strategic collaborations and a robust pipeline of research projects, the company plays a critical role in the biotech industry, pushing the boundaries of medical science.

CEO Mr. Carmine N. Stengone MBA, MS · 51 employees · United States · https://www.contineum-tx.com